COPD group: The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
Study summary
The purpose of this study is to establish the large COPD cohort and biological database in China, aiming for precision medicine to optimize diagnosis and treatment choices and to monitor and improve clinical outcomes in this disease.
Eligibility
Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Aged 40-75 years
* COPD group: baseline post-bronchodilator FEV1/FVC \< 0.7
* GOLD 0 group: individuals with chronic respiratory symptoms and/or high risk factors
* Signed informed consent obtained prior to participations with the ability to comply with protocol and be available for study visits over 5 years
Exclusion Criteria:
* Acute exacerbation in the past 3 months
* Having other respiratory diseases with massive lung tissue destruction such as severe bronchiectasis and tuberculosis, etc
* The usual criteria of serious uncontrolled diseases
* thoracic or abdominal surgery in the last 3 months
* eye surgery in the last three months
* retinal detachment
* myocardial infarction in the last 3 months
* admission to hospital for any cardiac condition in the last month
* heart rate over 120 beats per minute
* antibacterial chemotherapy for tuberculosis
* pregnant or breast feeding
Primary outcome measure(s)
COPD-related mortality and all-cause mortality — 10 years COPD-related mortality and all-cause mortality
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.